• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Leukemia and lymphoma >Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: Analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial
【24h】

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: Analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

机译：沙利度胺巩固可改善成纤维细胞生长因子受体表达正常但未上调的骨髓瘤的无进展生存期3：澳大利亚白血病和淋巴瘤MM6临床试验的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The translocation t(4;14) is associated with a poor prognosis in myeloma, but its effect in the setting of new drugs such as thalidomide, bortezomib and lenalidomide continues to be investigated, and the role of candidate genes such as FGFR3 (fibroblast growth factor receptor 3) is not yet clarified. In the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 randomized study comparing consolidation thalidomide and prednisolone with prednisolone alone following autologous stem cell transplant, patients on consolidation thalidomide and prednisolone had superior progression-free (PFS) and overall survival (OS). We now show that thalidomide consolidation benefited both t(4;14)-positive (PFS 29 vs. 17 months, p = 0.03) and -negative (52 vs. 24 months, p = 0.04) disease. PFS for patients with normal FGFR3 expression was significantly better than for those with up-regulated FGFR3 (31 vs. 21 months, p = 0.02). Consolidation thalidomide conferred an improved PFS in patients with normal FGFR3 expression (41 vs. 19 months, p = 0.02), but there was no improvement in patients with up-regulated FGFR3 (31 vs. 29 months, p = 0.76). We conclude that consolidation thalidomide may mitigate the poor prognostic effect of t(4;14), and improves PFS in normal but not up-regulated FGFR3 expression. Thus the level of FGFR3 expression provides additional prognostic information to t(4;14) in myeloma induction and consolidation therapy.
机译：t（4; 14）易位与骨髓瘤的预后不良有关，但仍在研究其在沙利度胺，硼替佐米和来那度胺等新药中的作用，以及候选基因如FGFR3（成纤维细胞生长）的作用因子受体3）尚不清楚。在澳大利亚白血病和淋巴瘤组（ALLG）进行的MM6随机研究中，比较了自体干细胞移植后巩固沙利度胺和泼尼松龙与单独泼尼松龙的疗效，合并沙利度胺和泼尼松龙的患者无进展（PFS）和总生存期（OS）更高。我们现在显示沙利度胺巩固有益于t（4; 14）阳性（PFS 29 vs. 17个月，p = 0.03）和-阴性（52 vs. 24个月，p = 0.04）。 FGFR3正常表达的患者的PFS明显优于FGFR3上调的患者（31个月与21个月，p = 0.02）。巩固沙利度胺可使FGFR3表达正常的患者的PFS改善（41 vs. 19个月，p = 0.02），而FGFR3上调的患者则无改善（31 vs. 29个月，p = 0.76）。我们得出的结论是巩固沙利度胺可能减轻t（4; 14）的不良预后作用，并改善正常但未上调FGFR3表达的PFS。因此，FGFR3表达水平为骨髓瘤诱导和巩固治疗中的t（4; 14）提供了更多的预后信息。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号